Allergan plc , announced positive results from CGP-MD-01, a Phase IIb/III clinical trial evaluating the efficacy, safety, and tolerability of...
Guardant Health, Inc. announces that the FDA has approved Guardant360 CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor).
Roche announced that the FDA has approved Foundation Medicine’s FoundationOne CDx as a companion diagnostic (CDx) for Roche’s Rozlytrek (entrectinib).
Foundation Medicine announced that it has received approval from the FDA for FoundationOneCDx to be used as a companion diagnostic for two groups of current and future FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies targeting BRAFV600E and BRAF/MEK inhibitor combination therapies targeting BRAFV600E or V600K mutations.
Foundation Medicine, Inc. announced it has received approval from the FDA for FoundationOneCDx to be used as a companion diagnostic...
The mortality of patients with hormone-resistant prostate cancer can be ascribed to a large degree to metastasis to distant organs, predominantly to the bones. In this review, we discuss the contribution of micro-RNAs (miRs) to...
Roche and Foundation Medicine, Inc. announced they have entered into a definitive merger agreement for Roche to acquire the outstanding...
Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 1 year of age and older.